Supernus Pharmaceuticals has narrowed its FY23 revenue forecast, bringing it closer to market expectations. This could potentially stabilize the stock as it reduces uncertainty around the company's future performance. However, the impact on the stock price will also depend on other factors such as the overall market condition and investor sentiment towards the pharmaceutical sector.